Severe deficiency of alpha-1 antitrypsin (AAT) can cause early-onset emphysema and several liver diseases, including cirrhosis, neonatal hepatitis and hepatocellular carcinoma.
The discovery of the structure and function of the AAT protein and the subsequent isolation and purification thereof have made possible alternative therapies aimed at preventing the progression of related pulmonary diseases (so-called additional therapies). The isolation of this gene and the advancement of gene therapy have further increased the possibility of specific treatment. Most specific treatments for AAT deficiency aim to increase plasma AAT levels (and thus elevated AAT concentrations in the interstitial lung) above the protection threshold. Other experimental therapeutic approaches attempt to interfere with the production of abnormal AAT proteins or to inhibit the polymerization of abnormal AAT proteins and to promote the secretion of AAT from hepatocytes. For patients with end-stage lung disease or liver disease, organ transplantation is another treatment option.
Currently, the most direct and effective way to increase AAT levels in plasma and interstitial lung is by intravenous infusion of pooled alpha-1 antitrypsin (pAAT).
The global Alpha 1 Antitrypsin Deficiency Treatment market is valued at 1190 million US$ in 2020 and will reach 2560 million US$ by the end of 2026, growing at a CAGR of 10.1% during 2021-2026. The objectives of this study are to define, segment, and project the size of the Alpha 1 Antitrypsin Deficiency Treatment market based on company, product type, end user and key regions.
This report studies the global market size of Alpha 1 Antitrypsin Deficiency Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Alpha 1 Antitrypsin Deficiency Treatment in these regions.
This research report categorizes the global Alpha 1 Antitrypsin Deficiency Treatment market by top players/brands, region, type and end user. This report also studies the global Alpha 1 Antitrypsin Deficiency Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
This report covers the present status and the future prospects of the global Alpha 1 Antitrypsin Deficiency Treatment market for 2015-2026.
The report offers detailed coverage of Alpha 1 Antitrypsin Deficiency Treatment industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Alpha 1 Antitrypsin Deficiency Treatment by geography. The report splits the market size, by volume and value, on the basis of application type and geography.
And in this report, we analyze global market from 5 geographies: Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru].
Key Companies
Augmentation Therapy, Bronchodilators, Corticosteroids, Oxygen Therapy,
Market Segment as follows:
Market by Order Type
Augmentation Therapy
Bronchodilators
Corticosteroids
Oxygen Therapy
Market size by End User
Hospitals
Specialty Clinics
Pharmacies
market while maintaining their competitive edge over their competitors. The report offers detailed and crucial information to understand the overall market scenario.
By Region
Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia]
Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
North America[United States, Canada, Mexico]
Middle East & Africa[GCC, North Africa, South Africa]
South America[Brazil, Argentina, Columbia, Chile, Peru]
The research provides answers to the following key questions:
• What is the estimated growth rate and market share and size of the Alpha 1 Antitrypsin Deficiency Treatment market for the forecast period 2021 - 2026?
• What are the driving forces in the Alpha 1 Antitrypsin Deficiency Treatment market for the forecast period 2021 - 2026?
• Who are the prominent market players and how have they gained a competitive edge over other competitors?
• What are the market trends influencing the progress of the Alpha 1 Antitrypsin Deficiency Treatment industry worldwide?
• What are the major challenges and threats restricting the progress of the industry?
• What opportunities does the market hold for the prominent market players?
Note – In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.